Citations

Clear

3314 citation(s) found for "Do, Alexander".

VP2: Mesenchymal Stem Cells and Local Tacrolimus Delivery Synergistically Enhance Neurite Extension
Saffari, Tara Sara, Saffari, Tiam M. , Chan, Katelyn, Chan, Katelyn, Borschel, Gregory Howard , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 5, 2022 | Volume: 10 | Issue: 1S | Pages: 13-13

10.1097/01.gox.0000817740.52584.33 Get It

A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act
Reihl, Sheantel , Patil, Nirav , Morshed, Ramin A, Mehari, Mulki, Aabedi, Alexander, Chukwueke, Ugonma N, Porter, Alyx B, Fontil, Valy , Cioffi, Gino, Waite, Kristin, Ostrom, Quinn, Barnholtz-Sloan, Jill, Hervey‐Jumper, Shawn L. , Ostrom, Quinn T. , Morshed, Ramin A. , Reihl, Sheantel J , Kruchko, Carol , Hervey-Jumper, Shawn L , Morshed, Ramin , Patil, Nirav , Mehari, Mulki, Aabedi, Alexander, Chukwueke, Ugonma N, Porter, Alyx B, Fontil, Valy , Cioffi, Gino, Waite, Kristin, Barnholtz-Sloan, Jill, Ostrom, Quinn T

Mayo Clinic

Neuro-Oncology | January 5, 2022 | Volume: 24 | Issue: 8 | Pages: 1341-1349

10.1093/neuonc/noac011 | PMID 34999844 Get It

Abstract Background The NIH Revitalization Act, implemented 29 years ago, set to improve the representation of women and minorities in clinical trials. In this study, we investigate progress made in all phase therapeutic clinical trials for neuroepithelial CNS tumors stratified by demographic-specific age-adjusted disease incidence and mortality. Additionally, we identify workforce characteristics associated with clinical trials meeting established accrual benchmarks. Methods Registry study of published clinical trials for World Health Organization defined neuroepithelial CNS tumors between January 2000 and December 2019. Study participants were obtained from PubMed and ClinicalTrials.gov. Population-based data originated from the CBTRUS for incidence analyses. SEER-18 Incidence-Based Mortality data was used for mortality analysis. Descriptive statistics, Fisher exact, and χ 2 tests were used for data analysis. Results Among 662 published clinical trials representing 49 907 participants, 62.5% of participants were men and 37.5% women (P < .0001) representing a mortality specific over-accrual for men (P = .001). Whites, Asians, Blacks, and Hispanics represented 91.7%, 1.5%, 2.6%, and 1.7% of trial participants. Compared with mortality, Blacks (47% of expected mortality, P = .008), Hispanics (17% of expected mortality, P < .001) and Asians (33% of expected mortality, P < .001) were underrepresented compared with Whites (114% of expected mortality, P < .001). Clinical trials meeting accrual benchmarks for race included minority authorship. Conclusions Following the Revitalization Act, minorities and women remain underrepresented in therapeutic clinical trials for neuroepithelial tumors, relative to disease incidence and mortality. Study accrual has improved with time. This study provides a framework for clinical trial accrual efforts and offers guidance regarding workforce considerations associated with enrollment of underserved patients.
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States
Hawley, Jessica E. , Sun, Tianyi , Chism, David D. , Duma, Narjust , Fu, Julie , Gatson, Na Tosha , Mishra, Sanjay , Nguyen, Ryan H., Reid, Sonya , Serrano, Oscar K. , Singh, Sunny , Venepalli, Neeta K. , Bakouny, Ziad , Bilen, Mehmet Asım , Choueiri, Toni K. , Dawsey, Scott J. , Fecher, Leslie A. , Flora, Daniel , Friese, Christopher R. , Glover, Michael , Gonzalez, Cyndi J, Goyal, Sharad , Khan, Hina, Lewis, Mark A. , McKay, Rana R. , Messing, Ian , Puc, Matthew , Ravindranathan, Deepak , Rhodes, Terence D., Rivera, Andrea Verghese, Roller, John , Shah, Sumit , Shaya, Justin , Streckfuss, Mitrianna, Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Shah, Dimpy P. , French, Benjamin , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Tadesse, Eyob, Lammers, Philip E. , Prete, Salvatore A. Del , Bär, Michael , Gulati, Anthony P., Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Lemmon, Christopher A. , Nizam, Amanda , Hoppenot, Claire , Bouchard, Gabrielle, Busser, Fiona, Connors, Jean M. , Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Allen, Eli Van, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Leighton, John, Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Clément, Jessica , Daher, Ahmad , Dailey, Mark, Jayaraj, Asha, Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Accordino, Melissa , Alexander, Mariam P., Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Gill, David , Low, Clarke A., Mashru, Sandeep H., Mansoor, Abdul-Hai, Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi , Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Faller, Bryan A. , Ajmera, Archana , Brouha, Sharon S. , Cabal, Angelo , Kligerman, Seth , Weissmann, Lisa B., Jani, Chinmay , Thomson, Carey C. , Knoble, Jeanna, Glace, Mary Grace, Stauffer, Karen, Zacks, Rosemary, Blau, Sibel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Misdary, Christian, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Jha, Alokkumar , Schapira, Lidia , Wu, Julie , Subbiah, Suki , Lopes, Gilberto , Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Karivedu, Vidhya , Lustberg, Maryam B. , Wall, Sarah , Williams, Nicole , Kasi, Anup , Edwin, Natasha, Smits, Melissa, Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Sueyoshi, Mark, Riess, Jonathan W. , Patel, Kanishka G. , Rubinstein, Samuel M. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christoper L., Bishnoi, Rohit , Russ, Atlantis Dawn, Rho, Young Soo , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Liu, Li , Khan, Mahir, Nguyen, Ryan H., Schwartz, Candice, Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , Duda, Stephany N. , Enriquez, Kyle T. , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Kennecke, Hagen F. , Schroeder, Brett A., Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Alimohamed, Saif, Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, Peddi, Prakash , Rosen, L, McCollough, Briana Barrow, LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Hawley, Jessica E , Mishra, Sanjay , Wu, Julie T , Xie, Zhuoer , Zubiri, Leyre , Gatson, Na Tosha N , Fiala, Mark A , Ahluwalia, Manmeet S , Lustberg, Maryam , Nguyen, Ryan H., Bashir, Babar , Caimi, Paolo F. , Hálfdánarson, Þorvarður R. , Hershman, Dawn L. , Labaki, Chris , Pennell, Nathan A , Schwartz, Gary K. , Thompson, Michael A. , Yu, Peter Paul , Warner, Jeremy L. , Hwang, Clara , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Henderson, Jeffrey P. , Zhou, Alice Y. , Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H., Rose, Suzanne J. , Barnholtz‐Sloan, Jill S. , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Xu, Vincent Eric , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa , Yeh, Albert C. , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Dailey, Mark, Elias, Rawad , Gadgeel, Shirish M. , Bhutani, Divaya , Reuben, Daniel Y. , Alexander, Mariam, Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Sachs, Zohar , Boland, Genevieve M. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Shah, Pankil , Hsiao, Albert , Rink, Cameron L. , Joshi, Monika , Griffiths, Elizabeth A. , Jabbour, Salma K , McNair, Christopher M. , Kloecker, Goetz Hans , Stover, Daniel G. , Gatti-Mays, Margaret Elena , Jhawar, Sachin R. , Palmer, Joshua D. , Wotman, Michael T. , Fazio, Alyson, Huber, Kathryn E. , Wood, William A. , Jensen, Christopher Edward , Kumar, Vaibhav , Wise-Draper, Trisha Michel , Gulati, Shuchi , Latif, Tahir , Shaikh, Hira , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Nguyen, Ryan H., Pasquinelli, Mary M. , Vikas, Praveen , Zaman, Qamar U., Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Aboulafia, David M. , Schroeder, Brett , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Network Open | January 4, 2022 | Volume: 5 | Issue: 1 | Pages: e2142046

10.1001/jamanetworkopen.2021.42046 | PMID 34982158 Get It

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Rahman, Zaid Abdel , Grenet, Justin , Boisclair, Stéphanie , Bewersdorf, Jan Philipp , Barth, Dylan , Fraga, Martina , Bixby, Dale L. , Zeidan, Amer M. , Desai, Pankil , Mannis, Gabriel N. , Deutsch, Yehuda E., Dinner, Shira, Frankfurt, Olga, Litzow, Mark R. , Al‐Kali, Aref , Foran, James M. , Sproat, Lisa Z., Jovanovic, Borko, Perl, Alexander E. , Altman, Jessica K. , Rahman, Zaid H. Abdel , Numan, Yazan , Abdel Rahman, Zaid, Bewersdorf, Jan P , Yilmaz, Musa , Litzow, Mark R. , Daver, Naval , Altman, Jessica K , Abdel Rahman, Zaid H , Zeidan, Amer M , Collins, Cailin T. , Yılmaz, Musa , Abaza, Yasmin , Daver, Naval

Mayo Clinic

American Journal of Hematology | January 4, 2022 | Volume: 97 | Issue: 3 | Pages: 322-328

10.1002/ajh.26447 | PMID 34981560 Get It

AbstractGilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3‐mutation (FLT3mut+). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either midostaurin as a component of standard intensive induction and consolidation or posttransplant FLT3 inhibitor maintenance. We performed a retrospective analysis using data from 11 US centers and where we identified 113 patients who received gilteritinib alone or as combination therapy for the treatment of R/R FLT3mut+ AML. The composite complete remission (CR) rate (CRc, defined as CR + CRi + CR with incomplete platelet recovery [CRp]) was 48.7% (n = 55). The CRc rate after treatment with gilteritinib in patients who were treated with only prior 7+3 and midostaurin with or without consolidation was 58% with a median survival of 7.8 months. Survival was longest in patients who obtained a CR, particularly a cMRD (clinical minimal or measurable residual disease) negative response; this remained significant after censoring at the time of stem cell transplant. The mitogen‐activated protein kinase pathway activating mutations that are known for gilteritinib resistance (NRAS, KRAS, and PTPN11) had lower CRc (35% vs. 60.5%) and lower median overall survival than patients' whose leukemia did not express these mutations (4.9 months vs. 7.8 months) (HR 2.4; 95% CI 1. 5.4) p value <.01.
A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy
Brien, Marie‐Eve , Gaudreault, Virginie, Hughes, Katia, Heazell, Alexander , Heazell, Alexander E P , Hayes, Dexter J. L. , Girard, Sylvie

Mayo Clinic

Journal of Clinical Medicine | January 3, 2022 | Volume: 11 | Issue: 1 | Pages: 225

10.3390/jcm11010225 | PMID 35011965 Get It

Blockade of the interleukin-1 (IL-1) pathway has been used therapeutically in several inflammatory diseases including arthritis and cryopyrin-associated periodic syndrome (CAPS). These conditions frequently affect women of childbearing age and continued usage of IL-1 specific treatments throughout pregnancy has been reported. IL-1 is involved in pregnancy complications and its blockade could have therapeutic potential. We systematically reviewed all reported cases of IL-1 blockade in human pregnancy to assess safety and perinatal outcomes. We searched several databases to find reports of specific blockade of the IL-1 pathway at any stage of pregnancy, excluding broad spectrum or non-specific anti-inflammatory intervention. Our literature search generated 2439 references of which 22 studies included, following extensive review. From these, 88 different pregnancies were assessed. Most (64.8%) resulted in healthy term deliveries without any obstetrical/neonatal complications. Including pregnancy exposed to Anakinra or Canakinumab, 12 (15.0%) resulted in preterm birth and one stillbirth occurred. Regarding neonatal complications, 2 cases of renal agenesis (2.5%) were observed, and 6 infants were diagnosed with CAPS (7.5%). In conclusion, this systematic review describes that IL-1 blockade during pregnancy is not associated with increased adverse perinatal outcomes, considering that treated women all presented an inflammatory disease associated with elevated risk of pregnancy complications.
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease
Abeykoon, Jithma P. , Dasari, Surendra , Ranatunga, Wasantha , Tischer, Alexander , Ravindran, Aishwarya , Tobin, W. Oliver , Nowakowski, Kevin E., Ruan, Gordon , Bennani, Nabila Nora, Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Patnaik, Mrinal M. , Wu, Xiaosheng , Lasho, Terra L. , Ranatunga, Wasantha K, Manske, Michelle K. , Ravindran, Aishwarya , Tobin, William Oliver, Ruan, Gordon J , Shah, Mithun V , Ryu, Jay H , Patnaik, Mrinal , Wu, Xiaosheng , Witzig, T.E. , Goyal, Guarav , Tobin, W Oliver , Vassallo, Robert , Tischer, Alexander , Rech, Karen L. , Young, Jason R. , Flanagan, Eoin P. , Shah, Meera , Koster, Matthew J. , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

American Journal of Hematology | January 3, 2022 | Volume: 97 | Issue: 3 | Pages: 293-302

10.1002/ajh.26441 | PMID 34978715 Get It

AbstractErdheim–Chester disease (ECD) is a histiocytic neoplasm that predominantly harbors mitogen‐activated protein kinase (MAPK) pathway variants. MAPK inhibitors typically are effective treatments, but mutations outside the MAPK pathway, such as CSF1R variants, may cause refractory ECD. We describe a patient with a novel somatic mutation in CSF1R (CSF1RR549_E554delinsQ) that resulted in refractory ECD affecting the central nervous system. Cell model studies, RNA sequencing analysis, and in silico protein modeling suggested that she had a gain‐of‐function mutation occurring in a region critical for autoinhibition. The patient was treated with pexidartinib, a CSF1R inhibitor, and has had a complete clinical and metabolic response lasting more than 1.5 years to date. To our knowledge, this is the first report to describe successful treatment of a patient with ECD by using an agent that specifically targets CSF1R. This case also highlights the critical role of individualized molecular profiling to identify novel therapeutic targets in ECD.
Solving the Conundrum of Eosinophils in Alloimmunity
Lynch, Cherie Alissa, Guo, Yizhan, Mei, Zhongcheng, Kreisel, Daniel, Gelman, Andrew E., Jacobsen, Elizabeth A., Krupnick, Alexander Sasha, Jacobsen, Elizabeth A. , Mei, Zhongcheng , Jacobsen, Elizabeth A , Lynch, Cherie Alissa, Guo, Yizhan, Mei, Zhongcheng, Kreisel, Daniel, Gelman, Andrew E., Krupnick, Alexander Sasha

Mayo Clinic

Transplantation | December 30, 2021 | Volume: 106 | Issue: 8 | Pages: 1538-1547

10.1097/tp.0000000000004030 | PMID 34966103 Get It

Eosinophils are bone-marrow-derived granulocytes known for their ability to facilitate clearance of parasitic infections and their association with asthma and other inflammatory diseases. The purpose of this review is to discuss the currently available human observational and animal experimental data linking eosinophils to the immunologic response in solid organ transplantation. First, we present observational human studies that demonstrate a link between transplantation and eosinophils yet were unable to define the exact role of this cell population. Next, we describe published experimental models and demonstrate a defined mechanistic role of eosinophils in downregulating the alloimmune response to murine lung transplants. The overall summary of this data suggests that further studies are needed to define the role of eosinophils in multiple solid organ allografts and points to the possibility of manipulating this cell population to improve graft survival.
Role of Echocardiography for Assessment of Cardiac Remodeling in Congenitally Corrected Transposition of Great Arteries
Egbe, Alexander C. , Miranda, William R. , Connolly, Heidi M.

Mayo Clinic

Circulation: Cardiovascular Imaging | December 28, 2021 | Volume: 15 | Issue: 1 | Pages: No page available

10.1161/circimaging.121.013477 | PMID 34961324 Get It

Background: The purpose of this study was to assess the role of echocardiography for a comprehensive assessment of cardiac remodeling, and the relationship between indices of cardiac remodeling and cardiovascular events (defined as the composite end point of heart failure hospitalization, heart transplant, or cardiovascular death) in adults with congenitally corrected transposition of great arteries (cc-TGA). Methods: This is a retrospective study of adults with cc-TGA who underwent echocardiogram (2003–2020). Offline image analysis was performed in all patients. Chamber (atrial and ventricular) function and size were assessed by strain imaging and 2-dimensional echocardiography. Results: Of 233 patients with cc-TGA (40±15 years), 123 (55%) had at least one cardiac procedure before baseline echocardiogram. Of 233 patients, 76% and 61% had left atrial dysfunction and systemic right ventricular dysfunction, respectively; while 43% and 11% had right atrial dysfunction and left ventricular dysfunction, respectively. During a median follow-up of 8.9 years, 114 (49%) underwent additional cardiac procedures, and 66 (28%) had cardiovascular events. Left atrial reservoir strain, right ventricular global longitudinal strain, right atrial reservoir strain, left ventricular systolic pressure, and left ventricular global longitudinal strain were independently associated with cardiovascular events. Conclusions: In addition to the clinical importance of right ventricular systolic dysfunction in cc-TGA that is already well described, the current study demonstrated, for the first time, that biatrial dysfunction was common and was associated with clinical outcomes. Since there are currently no effective therapies for atrial and ventricular dysfunction in patients with cc-TGA, there is a need for research to identify novel strategies to prevent atrial and ventricular dysfunction in this population.
Does Proximal Row Carpectomy Improve Union in Wrist Arthrodesis? A Retrospective Cohort Study
Bartoletta, John J. , Rioux-Forker, Dana , Patel, Raahil , Hinchcliff, Katharine M. , Shin, Alexander Y. , Rhee, Peter C. , Patel, Raahil S , Shin, Alexander Y , Hinchcliff, Katharine

Mayo Clinic

Journal of Wrist Surgery | December 24, 2021 | Volume: 11 | Issue: 04 | Pages: 344-352

10.1055/s-0041-1740400 | PMID 35971476 Get It

Abstract Background Some surgeons advocate for concomitant proximal row carpectomy (PRC) with total wrist arthrodesis (TWA), though there are limited data to support or oppose this view. Questions/Purposes Does concomitant PRC improve rates of union, revision, hardware loosening, hardware failure, and hardware removal in TWA? Patients and Methods A retrospective cohort study of patients who underwent TWA with and without concomitant PRC between January 2008 and December 2018 was undertaken. Patients were included if they underwent TWA using a dorsal spanning plate. Patients were excluded if they underwent partial wrist arthrodesis, revision TWA, or TWA with nondorsal spanning plate fixation. Results A total of 183 wrists in 180 patients were included in the study, 96 (52.5%) in the TWA only and 87 (47.5%) in the TWA + PRC groups. Median clinical and radiographic follow-up was 18.0 months (3.0–133.0 months) in the TWA + PRC group and 18.5 months (2.0–126.0 months) in the TWA only group (p = 0.907). No difference in nonunion (TWA + PRC: 13/87 [14.9%], TWA only: 18/96 [18.8%], odds ratio: 0.76, p = 0.494), revision (TWA + PRC: 5/87 [5.75%], TWA only: 8/96 [8.33%], hazard ratio [HR]: 0.73, p = 0.586), loosening (TWA + PRC: 4/87 [4.60%], TWA only: 6/96 [6.25%], HR: 0.74, p = 0.646), failure (TWA + PRC: 5/87 [5.75%], TWA only: 4/96 [4.17%], HR: 1.55, p = 0.530), and removal (TWA + PRC: 12/87 [13.8%], TWA only: 16/96 [16.7%], HR: 0.84, p = 0.634) were identified. Conclusion Concomitant PRC might not improve rates of union or diminish complications in patient undergoing TWA. The role of PRC and the rationale for its use in TWA need to be individualized and discussed with patients prior to surgery. Level of Evidence This is a Level IV, therapeutic study.
Time trend analysis of database and registry use in the neurosurgical literature: evidence for the advance of registry science
Asher, Anthony L. , Sammak, Sally El , Michalopoulos, Giorgos D. , Yolcu, Yagiz U. , Alexander, A. Yohan , Knightly, John J. , Foley, Kevin T. , Shaffrey, Christopher I. , Rose, Geoffrey, Coric, Domagoj , Bisson, Erica F. , Glassman, Steven D. , Mummaneni, Praveen V. , Bydon, Mohamad , Michalopoulos, Giorgos , Alexander, A Yohan , Harbaugh, Robert E. , Rose, Geoffrey A.

Mayo Clinic

Journal of Neurosurgery | December 24, 2021 | Volume: 136 | Issue: 6 | Pages: 1804-1809

10.3171/2021.9.jns212153 | PMID 34920432 Get It